Medicine Recommendations

Status Epilepticus

MHRA Drug Safety Update - Buccal midazolam (Buccolam▼): new authorised medicine for paediatric use

Status Epilepticus

Breathlessness

Care in the last weeks or days of life - Breathlessness in the last days of life AND Agitation/terminal restlessness in the last days of life

Palliative care emergencies - Seizures AND Anixolytic following major blood loss

Postural hypotension

Termination of pregnancy

Susceptible infections

Symptoms of overactive bladder (NICE TA290)

NICE TA290 - Mirabegron for treating symptoms of overactive bladder

*FOR BLACKPOOL CCG ONLY* - Where antimuscarinic agents are contraindicated or not tolerant.

*FOR MORECAMBE BAY CCG ONLY* - Mirabegron is recommended second line after at least two other NICE recommended therapies have been tried and either failed or not tolerated.

*FOR GREATER PRESTON, CHORLEY & SOUTH RIBBLE CCGS ONLY* - Restricted to third line use as per TA

Moderately to severely active ulcerative colitis (NICE TA925)

NICE TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis

Depressive illness

Depressive illness, social phobia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Narcolepsy

MHRA Drug Safety Update - Modafinil: now restricted to narcolepsy

Pain

MHRA Drug Safety Update - Drugs and driving: blood concentration limits set for certain drugs

Breathlessness

Pain in the last weeks or days of life

Breathlessness in the last days of life

Pain

Severe pain and breathlessness in patients with symptoms due to a palliative (life limiting) illness

PKU

Complex pain syndrome

MHRA Drug Safety Alert - Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men

MHRA Drug Safety Alert - Mycophenolate mofetil: pure red cell aplasia

MHRA Drug Safety Alert - Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

Off label indications as defined in the LSCMMG Shared Care Guidelines

Treatment of intermittent claudication in people with peripheral arterial disease (NICE TA223)

NICE TA223 - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease

NICE TA651 -  For treating opioid-induced constipation

Alcohol dependence (NICE TA325)

NICE TA325  Nalmefene for reducing alcohol consumption in people with alcohol dependence